RAQUALIA PHARMA INC.
Patent Owner
Stats
- 37 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- Feb 27, 2018 most recent publication
Details
- 37 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 428 Total Citation Count
- Mar 01, 1999 Earliest Filing
- 11 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9901571 Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonistsNov 02, 15Feb 27, 18[A61K, C07D]
9522140 Aryl substituted carboxamide derivatives as calcium or sodium channel blockersJul 02, 15Dec 20, 16[A61K, C07D]
9187463 Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acidMay 18, 12Nov 17, 15[C07D]
9101616 Aryl substituted carboxamide derivatives as calcium or sodium channel blockersMay 31, 10Aug 11, 15[A61K, C07D]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2015/0099,709 GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIAAbandonedMay 27, 13Apr 09, 15[A61K]
2012/0094,964 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTSAbandonedMay 06, 10Apr 19, 12[A61K, C07D, C07C, A61P]
2009/0291,977 Chromane Derivatives Useful As Acid Pump AntagonistsAbandonedDec 07, 05Nov 26, 09[A61K, C07D]
7138411 Substituted benzopyran derivatives for the treatment of inflammationExpiredNov 22, 02Nov 21, 06[A61K]
2005/0250,818 Ortho substituted aryl or heteroaryl amide compoundsAbandonedApr 29, 05Nov 10, 05[A61K]
6492390 Substituted benzopyran analogs for the treatment of inflammationExpiredMay 24, 01Dec 10, 02[A61K, C07D]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.